BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement...

BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private
Placement Offering

LYNBROOK, N.Y., June 10 /PRNewswire-FirstCall/ -- BioSpecifics
Technologies Corp. (OTC BB BSTC.OB-News) today announced that it sold an
aggregate of 100,000 unregistered shares of its common stock priced at $15 per
share for aggregate proceeds to BioSpecifics of $1,500,000. The shares were
purchased by certain private investors on June 9, 2008. The shares were sold
in a company managed PIPE transaction at a premium over the market price.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed and licensed injectable collagenase for three clinical indications.
It has a development and licensing agreement with Auxilium Pharmaceuticals,
Inc. for clinical indications in Dupuytren's disease, Peyronie's disease and
frozen shoulder (adhesive capsulitis).
BioSpecifics' main website is at
http://www.biospecifics.com

its Dupuytren's Disease patient discussion forum at
http://www.biospecifics.com/forum/index.html

and its Peyronie's Disease patient discussion forum at
http://www.biospecifics.com/forum/index2.html

SOURCE BioSpecifics Technologies Corp.

Thomas L. Wegman, President of BioSpecifics Technologies Corp.,
+1-516-593-7000